Gilead Sciences Inc. — Sponsor Intelligence | 42 EU Trials

Filter these 42 trials by condition, phase, country and more.

Open in Search →

42 Registered trials

13 Recruiting

28 Completed trials

19 Countries active

68 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I (Other)

Phase III: 16 Phase II/III: 6 Phase II: 10 Phase IV: 3 Phase I: 2 Phase I (Other): 4 Phase I (FiH): 1

Oversight events:

1 serious breach 14 temporary halts 2 urgent safety measures 4 unexpected events 1 corrective measure across 8 trials

View oversight register →

100%

28 of 28 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 2 Neoplasm malignant 1 Triple negative breast cancer 1 Chronic hepatitis 1 Endometrial cancer recurrent 1 Neoplasm 1 Small cell lung cancer extensive stage 1 Cutaneous lupus erythematosus 1 Rheumatoid arthritis 1 COVID-19 1 Hormone receptor positive breast cancer 1 Chronic hepatitis B 1

Top IMPs

SACITUZUMAB GOVITECAN 12 CARBOPLATIN 6 PACLITAXEL 6 EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR 5 PACLITAXEL ALBUMIN-BOUND 5 PEMBROLIZUMAB 5 DOMVANALIMAB 4 LENACAPAVIR 4 ZIMBERELIMAB 4 BICTEGRAVIR, LENACAPAVIR 3 CISPLATIN 3 DOCETAXEL 3

All trials

42 total

Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Pending

2024-511054-50-00 Phase II/III 6 countries EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; GS-1720; GS-4182
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus. Recruiting

2025-522729-36-00 Phase I (FiH) 4 countries GS-4321
Study of GS-5319 in Adults With Solid Tumors Recruiting

2025-522397-36-00 Phase I 1 country
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri… Recruiting

2024-516525-31-01 Phase III 13 countries SELADELPAR
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy Recruiting

2023-510022-33-00 Phase III 4 countries BICTEGRAVIR, LENACAPAVIR; EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; LEN…
Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting

2023-508304-38-00 Phase II 10 countries GS-1427
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal … Recruiting

2022-501684-40-00 Phase I (Other) 2 countries
Study of GS-0151 in Participants With Rheumatoid Arthritis Recruiting

2024-516520-34-00 Phase I (Other) 3 countries
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting

2024-515884-69-00 Phase III 11 countries SACITUZUMAB GOVITECAN; TOPOTECAN
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Phase III 6 countries CAPECITABINE; PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 Recruiting

2023-509428-16-00 Phase II/III 2 countries BICTEGRAVIR, LENACAPAVIR; LENACAPAVIR
Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting

2022-501119-14-01 Phase II 7 countries (PHOSPHONOOXY)METHYLN-[(S)-[1-(BICYCLO[1.1.1]PENTAN1-YL)-1H-1,2,3-TRIAZOL-4-YL](…
A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or… Recruiting

2022-501508-82-00 Phase I (Other) 3 countries
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting

2023-508302-24-00 Phase II 5 countries AVELUMAB; CARBOPLATIN; CISPLATIN; DOMVANALIMAB; ENFORTUMAB VEDOTIN; GEMCITABINE;…
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND-… Ended

2024-514047-28-00 Phase III 4 countries LENACAPAVIR, ISLATRAVIR; TENOFOVIR DISOPROXIL
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppres… Ended

2024-514046-37-00 Phase III 3 countries EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; LENACAPAVIR, ISLATRAVIR
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother… Ended

2024-511957-23-00 Phase III 7 countries DOXORUBICIN HYDROCHLORIDE; SACITUZUMAB GOVITECAN
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) Ended

2023-507891-31-00 Phase II/III 1 country LENACAPAVIR
Study with Various Immunotherapy Treatments in Participants With Lung Cancer Ended

2022-502916-35-01 Phase II 4 countries CARBOPLATIN; CISPLATIN; DOCETAXEL; DOMVANALIMAB; PACLITAXEL; PACLITAXEL ALBUMIN-…
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended

2022-502593-17-00 Phase III 11 countries CAPECITABINE; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; SACITUZUMAB GOVITECAN
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Ended

2022-500929-33-01 Phase II/III 4 countries BICTEGRAVIR; BICTEGRAVIR, LENACAPAVIR; LENACAPAVIR; LENACAPAVIR SODIUM
A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended

2022-501901-10-00 Phase IV 7 countries BULEVIRTIDE
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Phase III 8 countries DOMVANALIMAB; PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB; PEMETREXED; ZIMBERELIMAB
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U… Ended

2023-504194-21-00 Phase III 10 countries CARBOPLATIN; GEMCITABINE; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB; S…

Showing 1–24 of 42 trials

← All sponsors A–Z